Core Viewpoint - Boston Scientific has raised its fiscal year 2025 profit outlook to between $3.02 and $3.04 per share, driven by strong performance in its cardiovascular business [1] Financial Performance - Boston Scientific reported total sales exceeding $5 billion in Q3 2025, marking a 20.4% increase from $4.2 billion in Q3 2024 [3] - Revenue from the cardiovascular portfolio surpassed $3.3 billion, reflecting a 22.4% rise from $2.7 billion in Q3 2024 [3] - The MedSurg portfolio revenue grew to approximately $1.7 billion, a 16.4% increase year-over-year, while the urology segment rose by 28.1% to $682 million [6] Market Response - Following the Q3 results announcement, Boston Scientific's share price increased by over 4% to around $104 per share, with a market capitalization of approximately $153 billion [2] Product Performance - The Farapulse pulsed-field ablation (PFA) system has treated 500,000 patients, demonstrating consistent real-world results [3] - Adoption of the OPAL HDx Mapping System is contributing to the growth of Farapulse, with one in three Farapulse accounts utilizing the integrated FARAWAVE NAV PFA catheter and OPAL device [4] Competitive Landscape - Medtronic has also raised its FY26 profit outlook, reflecting growth in its cardiovascular portfolio, which is competing with Boston Scientific's Farapulse [4][5]